Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.53 |
| ▸ | TK1 | P04183 | 2/20 | 0.42 |
| ▸ | TK2 | O00142 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6834411 | 1.00 | RNASE1 (0.53) | RNASE1TK1TK2ALBPKM | |
| SCHEMBL6830885 | 0.94 | RNASE1 (0.45) | RNASE1TK1 | |
| SCHEMBL6834246 | 0.92 | RNASE1 (0.53) | RNASE1TK1TK2ALBPKM | |
| SCHEMBL7053656 | 0.92 | RNASE1 (0.53) | RNASE1TK1TK2 | |
| SCHEMBL6834245 | 0.92 | RNASE1 (0.53) | RNASE1TK1TK2ALBPKM | |
| SCHEMBL7566046 | 0.92 | RNASE1 (0.53) | RNASE1TK1TK2 | |
| SCHEMBL6573680 | 0.90 | RNASE1 (0.59) | RNASE1TK1TK2ALBPKM | |
| SCHEMBL6572381 | 0.90 | RNASE1 (0.59) | RNASE1TK1TK2ALBPKM | |
| SCHEMBL13666505 | 0.86 | POLB (0.45) | — | |
| SCHEMBL6835969 | 0.86 | POLB (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6750335-B2 | NUCLEOSIDE FOR USE IN THE GENERATION OF PREFERENTIAL OLIGONUCEOTIDES | NIGU CHEMIE GMBH (DE) | 2004-06-15 | — | — | US | disclosed |
| EP-1224198-B1 | NUCLEOSIDE DERIVATIVES WITH PHOTOLABILE PROTECTING GROUPS | NIGU CHEMIE GMBH (DE) | 2003-04-23 | — | — | EP | disclosed |
| US-20020146737-A1 | Nucleoside derivatives with photolabile protective groups | NIGU CHEMIE GMBH (DE) | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020146737-A1 | Nucleoside derivatives with photolabile protective groups | XRN2, XPA, NSUN2 | RNASE1 339/4885TK1 210/4885TK2 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.